Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaccine aims to stop stomach bug norovirus

NCT ID NCT06630117

Vaccine Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new vaccine called V330 to see if it is safe and how well it triggers an immune response against norovirus, a virus that causes vomiting and diarrhea. The trial included 245 healthy adults aged 18-49 and 60-79. Participants received either the vaccine or a placebo, and researchers monitored side effects and antibody levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
V330 vaccine
What this could lead to
If successful, this could lead to a safe vaccine that protects against norovirus, a common cause of severe stomach illness.
What could go wrong
This is an early Phase 1 trial focused on safety, not yet proving the vaccine works. It is small and results may not apply to larger populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

245 people

The number who actually took part.

Started

Mar 2024

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health prior to randomization * Is an individual from 18 to 49 years of age inclusive or from 60 to 79 years of age inclusive Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a history of myocarditis, pericarditis, and/or myopericarditis * Has a history of cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy

Contacts and locations

Locations

  • California Clinical Trials Medical Group managed by PAREXEL ( Site 0002)

    Glendale, California, 91206, United States

  • QPS-MRA, LLC-Early Phase ( Site 0006)

    South Miami, Florida, 33143, United States

  • Research Centers of America ( Hollywood ) ( Site 0004)

    Hollywood, Florida, 33024, United States

  • Velocity Clinical Research, Hallandale Beach ( Site 0003)

    Hallandale, Florida, 33009, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.